CoChat

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

Open access
Kim, Peter S., Kwilas, Anna R., Xu, Wenxin, Alter, Sarah, Jeng, Emily K., Wong, Hing C., Schlom, Jeffrey, Hodge, James W. · 2016 · Oncotarget
Cited by 156

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Peter S. Kim 1 , Anna R. Kwilas 1 , Wenxin Xu 2 , Sarah Alter 2 , Emily K. Jeng 2 , Hing C. Wong 2 , Jeffrey Schlom 1, * , James W. Hodge 1, * 1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 2 Altor BioScience Corporation, Miramar, FL, USA * These authors have contributed equally to this work Correspondence to: James W. Hodge, e-mail: jh241d@nih.gov Keywords: IL-15, IL-15 superagonist, NK cells, immunotherapy Received: September 02, 2015 Accepted: February 11, 2016 Published: February 18, 2016 ABSTRACT Interleukin (IL)-15-N72D superagonist-complexed with IL-15RαSushi-Fc fusion protein (IL-15SA/IL-15RαSu-Fc; ALT-803) has been reported to exhibit significant anti-tumor activity in murine myeloma, rat bladder cancer, and murine glioblastoma models. In this study, we examined the immunomodulatory and anti-tumor effects of IL-15SA/IL-15RαSu-Fc in tumor-free and highly metastatic tumor-bearing mice. Here, IL-15SA/IL-15RαSu-Fc significantly expanded natural killer (NK) and CD8 + T cells. In examining NK cell subsets, the greatest significant increase was in highly cytotoxic and migrating (CD11b + , CD27 hi ; high effector) NK cells, leading to enhanced function on a per-cell basis. CD8 + T cell subset analysis determined that IL-15SA/IL-15RαSu-Fc significantly increased IL-15 responding memory (CD122 + , CD44 + ) CD8 + T cells, in particular those having the innate (NKG2D + , PD1 − ) phenotype. In 4T1 breast tumor–bearing mice, IL-15SA/IL-15RαSu-Fc induced significant anti-tumor activity against spontaneous pulmonary metastases, depending on CD8 + T and NK cells, and resulting in prolonged survival. Similar anti-tumor activity was seen in the experimental pulmonary metastasis model of CT26 colon carcinoma cells, particularly when IL-15SA/IL-15RαSu-Fc was combined with a cocktail of checkpoint inhibitors, anti-CTLA-4 and anti-PD-L1. Altogether, these studies showed for the first time that IL-15SA/IL-15RαSu-Fc (1) promoted the development of high effector NK cells and CD8 + T cell responders of the innate phenotype, (2) enhanced function of NK cells, and (3) played a vital role in reducing tumor metastasis and ultimately survival, especially in combination with checkpoint inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7470

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 156

Metadata

Authors
Kim, P. S., Kwilas, A. R., Xu, W., Alter, S., Jeng, E. K., Wong, H. C., Schlom, J., & Hodge, J. W.
Venue
Oncotarget
Published
2016-02-18
Volume
7
Issue
13
Pages
16130-16145
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2299327880
Cited by
156
References
6
FWCI
9.42
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.